Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination
Source abstract
Abstract
Exploiting Toll-like receptor (TLR) agonists or their certain combinations can enhance the immune potency of subunit vaccine. Nevertheless, the design of co-delivery systems which can act in a synergistic and spatio-temporal way to achieve effective and durable specific immune response is still challenging. Here we fabricated mannose-functionalized lipid-hybrid polymersomes (MAN-IMO-PS) for co-delivery of ovalbumin antigen both inside the inner core and outside the lipid layer, TLR7/8 agonist imiquimod within the hydrophobic membrane, TLR4 agonist monophosphoryl lipid A in the lipid layer as programmed nanovaccine to synergistically activate immune responses for improving vaccine efficacy. After efficiently internalized by dendritic cells via mannose targeting and TLR4 ligating, MAN-IMO-PS significantly enhanced cross-presentation and cytokine production. In addition, MAN-IMO-PS showed depot effect at the injection site and enhanced migration to draining lymph nodes. Mice immunized with MAN-IMO-PS elicited greater lymphocyte activation, CD4+ and CD8+ T cell response, effector cytokines secretion, and induced Th-1 biased humoral responses. More importantly, prophylactic vaccination by MAN-IMO-PS significantly delayed tumor occurrence, suppressed tumor growth with prolonged survival, and achieved long-term immune effect. The present study demonstrates a rationally designed nanovaccine for combining antigen, different TLR agonists, and targeting moiety in a programmed manner to induce synergistic antitumor immune response.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Immune Response and Inflammation · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides10.1021/nn305466z ↗
2. Engineering nano- and microparticles to tune immunity10.1002/adma.201200446 ↗
3. Toll-like receptor control of the adaptive immune responses10.1038/ni1112 ↗
4. Toll-dependent selection of microbial antigens for presentation by dendritic cells10.1038/nature04596 ↗
5. Multifunctional nanoparticles for cancer immunotherapy: a groundbreaking approach for reprogramming malfunctioned tumor environment10.1016/j.jconrel.2018.01.028 ↗
6. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives10.1016/j.biomaterials.2007.04.023 ↗
7. Polymersomes for drug delivery: design, formation and characterization10.1016/j.jconrel.2011.10.005 ↗
8. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma10.1016/j.actbio.2017.06.017 ↗
9. Polymersomes: tough vesicles made from diblock copolymers10.1126/science.284.5417.1143 ↗
10. Bubble-generating polymersomes loaded with both indocyanine green and doxorubicin for effective chemotherapy combined with photothermal therapy10.1016/j.actbio.2018.05.033 ↗
11. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns10.1038/nri2868 ↗
12. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype10.1016/j.biomaterials.2012.03.041 ↗
13. Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation10.1016/j.biomaterials.2014.04.022 ↗
14. Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory10.1016/j.vaccine.2014.07.081 ↗
15. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles10.1016/j.addr.2011.05.017 ↗
16. Mannose receptor-targeted vaccines10.1517/14712598.4.12.1953 ↗
17. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?10.1016/S1471-4906(02)02281-0 ↗
18. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy10.1016/j.jconrel.2018.04.041 ↗
19. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development10.1016/j.jconrel.2017.01.004 ↗
20. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles10.1016/j.biomaterials.2018.04.003 ↗
21. Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization10.1021/mp400092y ↗
22. Cooperation of Toll-like receptor signals in innate immune defence10.1038/nri2038 ↗
23. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells10.1038/ni1223 ↗
24. Programming the magnitude and persistence of antibody responses with innate immunity10.1038/nature09737 ↗
25. Artificial bacterial biomimetic nanoparticles synergize pathogen-associated molecular patterns for vaccine efficacy10.1016/j.biomaterials.2016.03.039 ↗
26. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery
27. Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells10.1016/j.biomaterials.2013.10.009 ↗
28. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses10.1038/nmat2960 ↗
29. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines10.1586/erv.12.35 ↗
30. Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens10.1016/j.jconrel.2015.04.010 ↗
31. pH-responsive poly(D,L-lactic-co-glycolic acid) nanoparticles with rapid antigen release behavior promote immune response10.1021/nn5066793 ↗
32. Sample size calculation in animal studies using resource equation Approach10.21315/mjms2017.24.5.11 ↗
33. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model10.1016/j.ijpharm.2005.03.035 ↗
34. Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding10.1021/bm500337r ↗
35. Dendritic cells and the control of immunity10.1038/32588 ↗
36. Cross-presentation by dendritic cells10.1038/nri3254 ↗
37. Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy10.1016/j.biomaterials.2014.05.077 ↗
38. Mannose and mannose-6-phosphate receptor-targeted drug delivery systems and their application in cancer therapy
39. Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages: characterization and evidence for receptor recycling10.1016/0092-8674(80)90402-X ↗
40. C-Type lectin receptor(s)-targeted nanoliposomes: an intelligent approach for effective cancer immunotherapy10.2217/nnm-2017-0088 ↗
41. Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation10.1016/j.biomaterials.2014.10.037 ↗
42. Regulation of antigen transport into the cytosol for cross-presentation by ubiquitination of the mannose receptor10.1016/j.molimm.2012.10.010 ↗
43. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells10.4049/jimmunol.165.3.1182 ↗
44. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities10.4049/jimmunol.171.7.3385 ↗
45. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha10.1046/j.1365-2567.2003.01489.x ↗
46. A brief history of T cell help to B cells10.1038/nri3803 ↗
47. Effector and memory T-cell differentiation: implications for vaccine development10.1038/nri778 ↗
48. Dendritic-cell trafficking to lymph nodes through lymphatic vessels10.1038/nri1670 ↗
49. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells10.1038/334255a0 ↗
50. Interferons, immunity and cancer immunoediting10.1038/nri1961 ↗
51. Cytotoxic cells kill intracellular bacteria through granulysin-mediated delivery of granzymes10.1016/j.cell.2014.03.062 ↗
52. Immune system targeting by biodegradable nanoparticles for cancer vaccines10.1016/j.jconrel.2013.03.010 ↗
53. Multiple roles for CD4+ T cells in anti-tumor immune responses10.1111/j.1600-065X.2008.00616.x ↗
54. Central memory and effector memory T cell subsets: function, generation, and maintenance10.1146/annurev.immunol.22.012703.104702 ↗
55. Novel vaccine delivery system induces robust humoral and cellular immune responses based on multiple mechanisms10.1002/adhm.201300335 ↗
56. Introduction of soluble protein into the class I pathway of antigen processing and presentation10.1016/S0092-8674(88)91043-4 ↗